Comment
doi: 10.1007/s11886-009-0058-0.
AURORA and JUPITER trials: recognizing the limitations and expanding the benefits of statin treatment
Affiliations
- PMID: 19863863
- DOI: 10.1007/s11886-009-0058-0
Item in Clipboard
Comment
AURORA and JUPITER trials: recognizing the limitations and expanding the benefits of statin treatment
Curr Cardiol Rep.
2009 Nov.
No abstract available
Comment on
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. N Engl J Med. 2008. PMID: 18997196 Clinical Trial.
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28. Lancet. 2009. PMID: 19329177 Clinical Trial.
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. N Engl J Med. 2009. PMID: 19332456 Clinical Trial.
Similar articles
-
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.Vasc Health Risk Manag. 2009;5:1033-42. doi: 10.2147/vhrm.s6412. Epub 2009 Dec 29. Vasc Health Risk Manag. 2009. PMID: 20057896 Free PMC article. Review.
-
Impact of the JUPITER trial on statin prescribing for primary prevention.Pharmacotherapy. 2014 Jan;34(1):9-18. doi: 10.1002/phar.1340. Epub 2013 Aug 12. Pharmacotherapy. 2014. PMID: 23940007 Clinical Trial.
-
Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD.Int Urol Nephrol. 2010 Mar;42(1):133-6. doi: 10.1007/s11255-009-9649-3. Epub 2009 Oct 14. Int Urol Nephrol. 2010. PMID: 19826907 No abstract available.
-
From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):41-8. doi: 10.1161/CIRCOUTCOMES.108.832592. Epub 2009 Jan 13. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031811
-
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Adv Ther. 2009. PMID: 19444394 Review.
Cited by
-
Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis.Front Pharmacol. 2023 Jul 13;14:1050412. doi: 10.3389/fphar.2023.1050412. eCollection 2023. Front Pharmacol. 2023. PMID: 37521459 Free PMC article.